Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Bronchoscopy Study for Severe Asthma

28 mei 2015 bijgewerkt door: University of Pennsylvania

An Exploratory Study to Obtain Functional and Transcriptional/Translational Profiling of Cells From Bronchial Lavages and Brushings in Severe Asthmatics and Healthy Control Subjects

The purpose of this research study is to collect lung tissue and fluid from two groups of people: those who have severe asthma, and those who do not. These samples will then be tested in a laboratory to identify differences in the lung tissue cells and fluids that may exist between these two groups of people.

Studie Overzicht

Toestand

Ingetrokken

Interventie / Behandeling

Studietype

Observationeel

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

    • Pennsylvania
      • Philadelphia, Pennsylvania, Verenigde Staten, 19104
        • Airways Biology Initiative at the University of Pennsylvania

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar tot 65 jaar (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Bemonsteringsmethode

Niet-waarschijnlijkheidssteekproef

Studie Bevolking

10 severe asthma subjects matched with 10 healthy control subjects

Beschrijving

Inclusion Criteria:

  • Asthma Subject Inclusion Criteria

    1. Subject is an adult male or female between 18 and 65 years of age inclusive.
    2. Subject must have a pre-history of a physician's diagnosis of severe asthma (according to GINA classification) with some reversible airway obstruction (shown by peak flow or FEV1 in the last 12 months with a change of 12% in the absolute FEV1 measurement) and an exclusion of other significant pulmonary diseases (i.e., cystic fibrosis, tuberculosis, Interstitial Lung Disease and bronchopulmonary dysplasia)
    3. Subject has a positive methacholine test (PC20 < 16). This test sometimes cannot be performed in severe asthmatics because of low baseline FEV1 (< FEV1 50%). SABA reversibility of FEV1 is sufficient to define asthma in absence of MCh PC20.
    4. Subject's asthma has been stable for the past 30 days.
    5. The subject has been a non-smoker for the past year and should have less than a 10 pack year history.
    6. The subject must be capable of and willing to provide written informed consent
    7. The subject is able to understand and comply with protocol requirements and timetables, instructions and protocol-stated restrictions.
  • Healthy Subject Inclusion Criteria

    1. Subject is an adult male or female between 18 and 65 years of age inclusive. (Subjects will be age and gender matched) With age matching, we will enroll in a manner that age and gender will be matched 1:1 in the following cohorts: age 21-30, 31-40, 41-50, 51-60, 61-65.
    2. Subject must have an exclusion of asthma or other significant pulmonary diseases (i.e., cystic fibrosis, tuberculosis, Interstitial Lung Disease and bronchopulmonary dysplasia)
    3. The subject has been a non-smoker for the past year and should have less than a 10 pack year history.
    4. The subject has a negative methacholine test (PC20 > 16) and does not use inhaled steroids and/or SABA.
    5. The subject must be capable of and willing to provide written informed consent
    6. The subject is able to understand and comply with protocol requirements and timetables, instructions and protocol-stated restrictions.

      -

      Exclusion Criteria:

    1. As a result of the medical interview, physical examination or screening investigations, the physician responsible considers the volunteer unfit for the study.
    2. The subject has received an investigational drug or participated in any other research trial within 30 days or 5 half-lives, or twice the duration of the biological effect of any drug (whichever is longer), prior to the current study.
    3. No oral steroids within the last 3 months.
    4. No current anticoagulant and/or antiplatelet therapy.
    5. The subject has a history of alcohol or drug abuse within the last 5 years.
    6. The subject has history of hepatitis B, hepatitis C, or HIV virus.
    7. The subject has a history of chemotherapy or radiotherapy within the last 2 years.
    8. The subject has a history of diabetes.
    9. The subject is pregnant or lactating.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Cohorten en interventies

Groep / Cohort
Interventie / Behandeling
Severe Asthmatics
Subjects with a pre-existing physician diagnosis of asthma with reversible airflow obstruction of at least 12%.
Subjects will have a screening visit and, if they qualify to take part in the study, they will undergo a single bronchoscopy procedure. During the bronchoscopy, bronchoalveolar lavage (BAL) and bronchial brushings will be performed on each subject.
Andere namen:
  • Fiberoptic Bronchoscopy
  • Bronchoalveolaire lavage
Healthy non-smokers
Subjects will be never smokers or former smokers for the past year and less than 10 pack years lifetime with no history of asthma or any other lung disease.
Subjects will have a screening visit and, if they qualify to take part in the study, they will undergo a single bronchoscopy procedure. During the bronchoscopy, bronchoalveolar lavage (BAL) and bronchial brushings will be performed on each subject.
Andere namen:
  • Fiberoptic Bronchoscopy
  • Bronchoalveolaire lavage

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Tijdsspanne
To obtain bronchial brushings and bronchial alveolar lavage fluid from 10 subjects with severe asthma (GINA criteria in The Global Initiative for Asthma, http://www.ginasthma.org ) and from 10 matched normal healthy subjects.
Tijdsspanne: 1 year
1 year

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Medewerkers

Onderzoekers

  • Hoofdonderzoeker: Reynold Panettieri, MD, University of Pennsylvania

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start

1 januari 2013

Primaire voltooiing (Verwacht)

1 december 2014

Studie voltooiing (Verwacht)

1 december 2014

Studieregistratiedata

Eerst ingediend

6 december 2012

Eerst ingediend dat voldeed aan de QC-criteria

6 december 2012

Eerst geplaatst (Schatting)

10 december 2012

Updates van studierecords

Laatste update geplaatst (Schatting)

1 juni 2015

Laatste update ingediend die voldeed aan QC-criteria

28 mei 2015

Laatst geverifieerd

1 oktober 2011

Meer informatie

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Klinische onderzoeken op Ernstig aanhoudend astma

Abonneren